Avantor, Inc. $AVTR Position Boosted by New York State Common Retirement Fund

New York State Common Retirement Fund raised its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 25.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 421,814 shares of the company’s stock after acquiring an additional 84,587 shares during the period. New York State Common Retirement Fund owned approximately 0.06% of Avantor worth $5,264,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in AVTR. EverSource Wealth Advisors LLC increased its holdings in shares of Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after purchasing an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC bought a new position in Avantor in the 2nd quarter valued at about $32,000. FNY Investment Advisers LLC acquired a new position in Avantor during the 2nd quarter valued at about $36,000. Osaic Holdings Inc. increased its stake in Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after buying an additional 1,064 shares during the period. Finally, Farther Finance Advisors LLC raised its position in shares of Avantor by 172.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,709 shares of the company’s stock worth $46,000 after buying an additional 2,346 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Trading Down 3.2%

Avantor stock opened at $10.79 on Friday. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of -82.96, a price-to-earnings-growth ratio of 3.86 and a beta of 0.94. Avantor, Inc. has a 1 year low of $10.62 and a 1 year high of $22.44. The firm’s 50 day moving average price is $11.52 and its two-hundred day moving average price is $12.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.49.

Insider Activity

In related news, Director Sanjeev K. Mehra bought 350,000 shares of Avantor stock in a transaction dated Friday, December 5th. The stock was acquired at an average cost of $11.09 per share, with a total value of $3,881,500.00. Following the completion of the acquisition, the director directly owned 350,000 shares in the company, valued at approximately $3,881,500. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AVTR shares. Bank of America cut shares of Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price objective for the company. in a report on Monday, December 15th. Barclays restated an “equal weight” rating and issued a $12.00 target price (down from $15.00) on shares of Avantor in a research report on Thursday, October 30th. Zacks Research raised Avantor from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. Robert W. Baird lifted their price target on Avantor from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Finally, Raymond James Financial lowered Avantor from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.60.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.